Monomethyl auristatin E-conjugated anti-EGFR antibody inhibits the growth of human EGFR-positive non-small cell lung cancer
- PMID: 31037333
- DOI: 10.1007/s00280-019-03848-9
Monomethyl auristatin E-conjugated anti-EGFR antibody inhibits the growth of human EGFR-positive non-small cell lung cancer
Abstract
Purpose: Epidermal growth factor receptor (EGFR) is highly expressed on non-small cell lung cancers (NSCLC) and a valuable therapeutic target. This study aimed at producing and characterizing monomethyl auristatin E (MMAE)-conjugated anti-EGFR antibody as a novel EGFR-targeting therapy for NSCLC.
Methods: A humanized anti-EGFR monoclonal antibody (named RC68) was purified and conjugated with MMAE using a MC-VC-PAB or PY-VC-PAB linker. The in vitro and in vivo antitumor activity of RC68-MC-VC-PAB-MMAE and RC68-PY-VC-PAB-MMAE were characterized.
Results: The RC68 was generated from RC68-expressing cells and had a purity of > 99.0%. The RC68 recognized EGFR on tumor cells, particularly for higher EGFR expressing H125, A431, HCC827 and H1975 cells. The RC68 was conjugated with an average of 4 MMAE molecules to generate RC68-MC-VC-PAB-MMAE and RC68-PY-VC-PAB-MMAE, respectively. The RC68-MC-VC-PAB-MMAE, RC68-PY-VC-PAB-MMAE and RC68 displayed similar binding affinity to EGFR on tumor cells, and RC68-MC-VC-PAB-MMAE and RC68-PY-VC-PAB-MMAE were effectively internalized by H125 cells. The RC68-MC-VC-PAB-MMAE and RC68-PY-VC-PAB-MMAE inhibited the growth of H125 cells in vitro with an IC50 7.37-8.04 ng/mL and implanted H125 tumors in vivo, but did not affect body weights of mice. The antitumor effect of RC68-MC-VC-PAB-MMAE was stronger than RC68-PY-VC-PAB-MMAE, which was also stronger than docetaxel in vivo.
Conclusions: These novel antibody-drug conjugates, particularly for RC68-MC-VC-PAB-MMAE, may be a potential candidate for treatment of EGFR + NSCLC.
Keywords: Antibody–drug conjugates; Epidermal growth factor receptor; Monoclonal antibody; Non-small cell lung cancer.
Similar articles
-
Development of a Novel EGFR-Targeting Antibody-Drug Conjugate for Pancreatic Cancer Therapy.Target Oncol. 2019 Feb;14(1):93-105. doi: 10.1007/s11523-018-0616-8. Target Oncol. 2019. PMID: 30635821
-
An EGFR-targeting antibody-drug conjugate LR004-VC-MMAE: potential in esophageal squamous cell carcinoma and other malignancies.Mol Oncol. 2019 Feb;13(2):246-263. doi: 10.1002/1878-0261.12400. Epub 2018 Nov 15. Mol Oncol. 2019. PMID: 30372581 Free PMC article.
-
HER2-targeted antibody drug conjugates for ovarian cancer therapy.Eur J Pharm Sci. 2016 Oct 10;93:274-86. doi: 10.1016/j.ejps.2016.08.015. Epub 2016 Aug 7. Eur J Pharm Sci. 2016. PMID: 27509865
-
Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer.Semin Oncol. 2005 Apr;32(2 Suppl 3):S35-41. doi: 10.1053/j.seminoncol.2005.03.008. Semin Oncol. 2005. PMID: 16015534 Review.
-
Disitamab Vedotin: First Approval.Drugs. 2021 Nov;81(16):1929-1935. doi: 10.1007/s40265-021-01614-x. Drugs. 2021. PMID: 34661865 Review.
Cited by
-
Peptibody Based on FGFR1-Binding Peptides From the FGF4 Sequence as a Cancer-Targeting Agent.Front Pharmacol. 2021 Nov 12;12:748936. doi: 10.3389/fphar.2021.748936. eCollection 2021. Front Pharmacol. 2021. PMID: 34867353 Free PMC article.
-
Intrinsically Fluorescent Oligomeric Cytotoxic Conjugates Toxic for FGFR1-Overproducing Cancers.Biomacromolecules. 2021 Dec 13;22(12):5349-5362. doi: 10.1021/acs.biomac.1c01280. Epub 2021 Dec 2. Biomacromolecules. 2021. PMID: 34855396 Free PMC article.
-
Advances in epidermal growth factor receptor specific immunotherapy: lessons to be learned from armed antibodies.Oncotarget. 2020 Sep 22;11(38):3531-3557. doi: 10.18632/oncotarget.27730. eCollection 2020 Sep 22. Oncotarget. 2020. PMID: 33014289 Free PMC article. Review.
-
Novel development strategies and challenges for anti-Her2 antibody-drug conjugates.Antib Ther. 2022 Jan 27;5(1):18-29. doi: 10.1093/abt/tbac001. eCollection 2022 Jan. Antib Ther. 2022. PMID: 35146330 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous